Artivion, Inc. · NYSE:AORT

Artivion — Investor Presentation (May 2026)

20 slides from Artivion's investor presentation, May 2026

  1. Slide 1: Corporate Overview

    Corporate Overview May 2026 © 2026 Artivion, Inc. 1

  2. Slide 2: Forward-Looking Statement

    FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management’s beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect

  3. Slide 3: An Aortic Disease-Focused Company

    AN AORTIC DISEASE-FOCUSED COMPANY ~$444 MILLION FY25 REVENUE; ~$90 MILLION FY25 EBITDA AORTIC VALVE STENOSIS <65 YRS ALLOGRAFT MECHANICAL VALVES VALVES AORTIC DISSECTION & ANEURYSMS Aneurysm SURGICAL STENT SEALANT GRAFTS Dissection © 2026 Artivion, Inc. 3

  4. Slide 4: Experienced Leaders

    EXPERIENCED LEADERS Decades of combined experience and leadership in the medical device industry. Lance Berry John Davis Jean Holloway Simona Zannetti EVP, COO & CFO Chief Commercial Officer SVP, GC, CCO & CS SVP, Clinical Research & Chief Medical Officer Pat Mackin Chairman, President & CEO Previou

  5. Slide 5: Driving Sustained Double-Digit Revenue Growth & 2x+ EBITDA Growth

    DRIVING SUSTAINED DOUBLE-DIGIT REVENUE GROWTH & 2x+ EBITDA GROWTH Highly Differentiated, High Growth, Gross Margin Highly Defendable High Margin Expansion + Double Digit Base Business Businesses SG&A Leverage Revenue Growth Stent 2x+ Preservation  Gross margin Services Grafts expansion through mix

  6. Slide 6: Highly Differentiated, Highly Defendable Base Business

    HIGHLY DIFFERENTIATED, HIGHLY DEFENDABLE BASE BUSINESS Strong Positions in Segments with Limited Competition and No Anticipated New Entrants Market 2025 # Major Growth Differentiation Global TAM Position/ Revenue Competitors Profile Share Only Preservation Mid Decellularized Services $96M $150M #1 /

  7. Slide 7: On-X Aortic Heart Valve Post Approval Study vs. PROACT IDE

    ON-X AORTIC HEART VALVE POST APPROVAL STUDY (PAS) VS. PROACT IDE 5-year real-world results demonstrate even better patient outcomes than predicted by the On-X aortic heart valve PROACT IDE study COMPOSITE PRIMARY ENDPOINT Only Mechanical 5.39% vs 1.83%, p<0.0001; N=229 Heart Valve Maintained at a Lo

  8. Slide 8: On-X: High Growth, High Margin, with Market Upside

    On-X: High Growth, High Margin, with Market Upside New Recently Published Data Across Three Leading Journals to Drive Potential $100 million Upside to Addressable U.S. Mechanical Heart Valve Market 5-year PAS Data Presented in April 20241  Demonstrated 87% Reduction in Major Bleeding  Validated On

  9. Slide 9: On-X Low INR Indication Driving Durable Double-Digit Growth & Share Gains

    ON-X LOW INR INDICATION DRIVING DURABLE DOUBLE-DIGIT GROWTH & SHARE GAINS* Growth Accelerated by New Clinical Data Unlocking New Incremental $100M U.S. Market 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 70% 62% Original Approval of Low INR Claim 34% 30% FY25 ON-X SALES 21% GROWTH Y/Y *Market s

  10. Slide 10: High Growth Stent Graft Business

    HIGH GROWTH STENT GRAFT BUSINESS  Focused on More Complex, Less Competitive Segments  Artivion Stent Graft Growth: 18% 3-year CAGR Advanced Stent Graft Segment Mature Stent Graft Segment MARKET GROWTH RATE: MID-TEENS MARKET GROWTH RATE: MID-SINGLE DIGITS Frozen Elephant Trunk (E-vitaTM Open Neo) C

  11. Slide 11: Humanitarian Device Exemption Enables Early U.S. Launch of AMDS

    HUMANITARIAN DEVICE EXEMPTION ENABLES EARLY U.S. LAUNCH OF AMDSTM  High Growth, High Margin Business with Limited Competitive Alternatives  Strong Early Market Traction with Unparalleled Clinical Benefits Supported by Growing Body of Evidence  New MS-DRG Code 209, effective October 1, 2025  PMA

  12. Slide 12: AMDS PERSEVERE US IDE Study Primary Endpoints

    AMDSTM PERSEVERE US IDE Study Primary Endpoints Full IDE data demonstrates AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarch control ACUTE DEBAKEY TYPE I (ADTI) Through Hospital WITH MALPERFUSION Full 30-Day Discharge Data Data Hemiarch Reference Cohort Avg.¹ (n=7

  13. Slide 13: R&D Pipeline

    R&D PIPELINE Regulatory Path Addressable Market 2026 2027 2028 2029 Hybrid Acute Type A Dissection US PMA* $150M (ATAD) Prosthesis AMDS Japan $75M 2026 2026 Endovascular Arch Branch US PMA $150M System Endospan’s NEXUS Japan $100M Hybrid Frozen Elephant Trunk US PMA $80M Arcevo LSA Japan $50M > 2029

  14. Slide 14: Endospan NEXUS TRIOMPHE US IDE Trial

    Endospan NEXUS ® TRIOMPHE US IDE Trial 30-day data demonstrate 63% reduction in major adverse event (MAE) Presented at rate compared to the reference performance goal AATS 2026 30-DAY DATA 1 TRIOMPHE Performance p Value (n=54) Goal MAEs2 >=1 13.0% 35.0% p<0.001 Technical Failure 1.9% 30.0% p<0.001 3

  15. Slide 15: ARTIZEN Pivotal IDE Study

    ARTIZEN PIVOTAL IDE STUDY Prospective, Non-randomized, Non-blinded, Double-arm, Multicenter (US & EU ≈ 30 Sites) PRIMARY PATIENT GROUP 117 patients: Chronic dissection or Aneurysm Primary endpoint: Freedom from major adverse events (MAEs) within 1-year post-index procedure: all-cause mortality, new

  16. Slide 16: Differentiated Business Model with Highly Leverageable Global Infrastructure

    DIFFERENTIATED BUSINESS MODEL WITH HIGHLY LEVERAGEABLE GLOBAL INFRASTRUCTURE Significant EBITDA Margin Expansion Opportunity Gross Margin Scalable Global Leverageable Global Reinvesting in R&D Expansion Sales Force G&A Infrastructure Highly Accretive Product ~200 Global Direct Sales Consistent inves

  17. Slide 17: EBITDA Margin Expansion & Deleveraging

    EBITDA MARGIN EXPANSION & DELEVERAGING Supported by Strong Balance Sheet & Prudent Capital Management ADJUSTED EBITDA MARGIN NET DEBT LEVERAGE 1.8x NET DEBT As of March 31, 2026 6.7x s 4.8x 20% 3.8x 18% 1.8x 15% 13% 2022 2023 2024 2025 2022 2023 2024 2025 © 2026 Artivion, Inc. 17 *Graphs are not to

  18. Slide 18: Full Year 2026 Revenue Guidance

    FULL YEAR 2026 REVENUE GUIDANCE GROWTH DRIVERS + Continued strength in existing products On-X and aortic stents $90.0M + Positive new data supporting the benefits of AMDS and On-X aortic valves $480M- Revenue* ($) $443.6M $496M + Continued adoption of AMDS following Y/Y cc. 13% 7-11% receipt of Huma

  19. Slide 19: Revenue Growth and Operating Leverage to Drive Adjusted EBITDA Expansion

    REVENUE GROWTH AND OPERATING LEVERAGE TO DRIVE ADJUSTED EBITDA EXPANSION FULL YEAR 2026 ADJUSTED EBITDA EXPECTATIONS* DRIVERS Expect continued operating leverage to be $90.0M driven by gross margin expansion, global sales force and G&A infrastructure $100M- Adjusted EBITDA ($) $89.6M $107M *Excludes

  20. Slide 20: © 2026 Artivion, Inc.

    © 2026 Artivion, Inc.

Artivion — Investor Presentation (May 2026) on 6ix